Trial Profile

Safety and Efficacy of QHRD107 Capsule Combined With Venclexta and Azacitidine in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia: a Single-arm, Open, Multicenter Phase IIa Study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs QHRD 107 (Primary) ; Azacitidine; Venetoclax
Indications Acute myeloid leukaemia
Focus Adverse reactions; Therapeutic Use
Sponsors Changzhou Qianhong Bio-pharma

Most Recent Events

10 Dec 2024 Preliminary Results, As of July 19, 2024, 28 patients were screened across 10 sites in China, with 24 treated with the 107VA regimen. Of these, 13 patients were enrolled in dose escalation phase and 11 in the expansion phase presented at the 66th American Society of Hematology Annual Meeting and Exposition
09 Aug 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com